Van Buren Peter Noel, Inrig Jula K
University of Texas Southwestern Medical Center, Department of Internal Medicine and Division of Nephrology, Dallas, TX, USA.
Blood Purif. 2016;41(1-3):188-93. doi: 10.1159/000441313. Epub 2016 Jan 15.
Intradialytic hypertension is a condition where there is an increase in blood pressure (BP) from pre- to post-hemodialysis; this condition has been recently identified as an independent mortality risk factor in hypertensive hemodialysis patients. The mechanisms and management of intradialytic hypertension have been explored in numerous research studies over the past few years.
Patients with intradialytic hypertension have been found to be more chronically volume overloaded compared to other hemodialysis patients, although no causal role has been established. Patients with intradialytic hypertension have intradialytic vascular resistance surges that likely explain the BP increase during dialysis. Acute intradialytic changes in endothelial cell function have been proposed as etiologies for the increase in vascular resistance, although it is unclear if endothelin-1 or some other vasoconstrictive peptide is responsible. There is an association between dialysate to serum sodium gradients and BP increase during dialysis in patients with intradialytic hypertension, although it is unclear if this is related to endothelial cell activity or acute osmolar changes. In addition to probing the dry weight of patients with intradialytic hypertension, other management strategies include lowering dialysate sodium and changing antihypertensives to include carvedilol or other poorly dialyzed antihypertensives.
Hemodialysis patients with intradialytic hypertension have an increased mortality risk compared to patients with modest decreases in BP during dialysis. Intradialytic hypertension is associated with extracellular volume overload in addition to acute increases in vascular resistance during dialysis. Management strategies should include reevaluation of dry weight and modification of both the dialysate prescription and medication prescription.
透析中高血压是指血液透析前后血压(BP)升高的一种情况;这种情况最近被确定为高血压血液透析患者的一个独立死亡风险因素。在过去几年中,众多研究探讨了透析中高血压的机制和管理方法。
与其他血液透析患者相比,透析中高血压患者被发现长期存在更多的容量超负荷情况,尽管尚未确定因果关系。透析中高血压患者存在透析中血管阻力激增的情况,这可能解释了透析期间血压升高的原因。内皮细胞功能的急性透析中变化已被提出作为血管阻力增加的病因,尽管尚不清楚是内皮素-1还是其他一些血管收缩肽起作用。透析液与血清钠梯度与透析中高血压患者透析期间血压升高之间存在关联,尽管尚不清楚这是否与内皮细胞活性或急性渗透压变化有关。除了探究透析中高血压患者的干体重外,其他管理策略包括降低透析液钠浓度以及更换抗高血压药物,改用卡维地洛或其他透析性差的抗高血压药物。
与透析期间血压适度下降的患者相比,患有透析中高血压的血液透析患者死亡风险增加。透析中高血压除了与透析期间血管阻力急性增加有关外,还与细胞外容量超负荷有关。管理策略应包括重新评估干体重以及调整透析液处方和药物处方。